Shire Horse LLC

Pfizer, founded in 1849, is one of the largest research-based pharmaceuticals companies in the United States. The company s areas of expertise include human and animal health, and consumer health care products. Its human health segment offers medicines for cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye diseases and allergies. The consumer health care segment produces and markets various medications for oral care, upper respiratory and gastrointestinal health, tobacco dependence, skin and eye care, and hair growth. The company s animal health division develops products for the prevention and treatment of diseases in livestock and companion animals. The products offered by the division include parasiticides, anti-inflammatories, vaccines, and antibiotics. The company s well-known brands include Sudafed, Listerine, Benadryl, Lipitor, Diflucan, Zithromax, Viagra and Celebrex. It also produces pharmaceutical chemicals and gelatin capsules, and offers contract-manufacturing services. Pfizer has various subsidiaries, including Warner-Lambert, Parke-Davis, and Goedecke, and is headquartered in New York City.

Immunomedics strives to improve health care and extend life by focusing on the development and commercialization of humanized monoclonal antibody-based treatments for cancer, autoimmune and other serious diseases. The Food and Drug Administration recently fast tracked the company s leading drug candidate, Epratuzumab for the potential treatment of the world s estimated 3 million sufferers of lupus. Immunomedics is traded publicly on NASDAQ under the symbol IMMU and maintains corporate headquarters in Morris Plains, N.J.

Palatin Technologies is a biopharmaceutical research and development company with a focus on developing melanocortin-based therapeutics. Additionally, the company has a pipeline of product opportunities in development. The company s internal research and development capability, anchored by its proprietary MIDAS drug-discovery technology platform, is the core of its new product development program. Palatin s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize its commercial potential. The company's flagship proprietary product is Bremelanotide, an intranasally administered melanocortin receptor agonist in development for the treatment of both male and female sexual dysfunction. Palatin Technologies has formed a strategic alliance with King Pharmaceuticals to jointly develop and commercialize Bremelanotide. Palatin Technologies maintains its corporate headquarters in Cranbury, N.J.